Loading...
IL-17 inhibitors — including secukinumab (Cosentyx®, Novartis), ixekizumab (Taltz®, Eli Lilly), brodalumab (Siliq®, Bausch Health / Kyntheum®, LEO Pharma) — are reshaping treatment for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Yet patient awareness, treatment access, and guideline shifts continue to influence real-world adoption. “Public Awareness and Perception of IL-17 Inhibitors in Dermatology Care” analyzes one year of online patient and community conversations across the U.S., offering actionable insights for pharmaceutical companies, payers, and healthcare providers. This dermatology market research report covers:
The expanding role of IL-17 inhibitors in psoriasis and related immune-mediated diseases.
Patient sentiment toward biologic innovation, treatment effectiveness, and safety.
Access challenges, including insurance coverage, affordability, and limited support programs.
Lifestyle and environmental influences and seasonal triggers.
The impact of clinical guidelines (e.g., NICE recommendations) on treatment pathways and eligibility.
Strategic considerations for pharma, payers, and HCPs in building more patient-centered dermatology care models.